Want to see VANI full AI Analyst Report?
VANI Stock Chart & Stats
$1.42
$0.02(1.56%)
At close: 4:00 PM EDT
$1.42
$0.02(1.56%)
Day’s Range― - ―
52-Week Range$0.92 - $1.81
Previous CloseN/A
Volume59.57K
Average Volume (3M)186.29K
Market Cap
$101.03M
Enterprise Value$105.99M
Total Cash (Recent Filing)$19.89M
Total Debt (Recent Filing)$17.86M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Nov 18, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding90,203,354
10 Day Avg. Volume185,098
30 Day Avg. Volume186,286
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-815.30
Enterprise Value/Ebitda-3.95
Forecast
1Y Price Target
$4.00Price Target Upside181.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ExecutionCompleting the Phase 1 enrollment and dosing program ahead of schedule demonstrates effective clinical execution and advances NPM-139 toward important development milestones. Top-line data could support an IND filing and a planned Phase 2 study, creating a clearer path for the lead asset.
External Platform ValidationNovo Nordisk’s evaluation agreement provides external validation for Vivani’s implantable GLP-1 delivery approach and NanoPortal technology. Although non-exclusive and not proof of commercial success, the relationship may improve scientific credibility and support future partnering potential.
Strategic Cost FocusSeparating Cortigent through the planned merger could reduce Vivani’s direct neurostimulation spending and sharpen management focus on its metabolic drug-delivery programs. A more concentrated capital allocation strategy may help preserve resources for NPM-139 development.
Bears Say
No Commercial RevenueVivani remains a development-stage company without commercial revenue, while recurring losses remain in the mid-$20 million range. This limits internally generated funding, leaves profitability dependent on successful clinical development, and delays evidence of sustainable operating leverage.
Persistent Cash BurnLarge negative operating and free cash flow shows that Vivani’s research and corporate spending continue to consume substantial cash. Sustained burn can reduce the resources available for clinical programs and increase the likelihood that future development requires additional financing.
Meaningful LeverageDebt is close to the company’s equity base while losses remain substantial, creating financial pressure for a clinical-stage business. Meaningful leverage can reduce flexibility during development delays and may increase dependence on future capital to support ongoing operations.
Vivani Medical News
VANI FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was $0.92 and its highest was $1.81 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is $101.03M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Nov 18, 2026 which is in 26 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Aug 13, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.083 by $0.013.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.09.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 90,203,354 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.083. Following the earnings report the stock price went up 4.478%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in VANI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (181.69% Upside)
$4.00 (181.69% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.95%
12-Months-Change
Fundamentals
Return on Equity
-191.05%
Trailing 12-Months
Asset Growth
44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
VANI Stock 12 Month Forecast
Average Price Target
$4.00
▲(181.69% Upside)
Technical Analysis
Ownership Overview
50.60% Insiders
2.19% Mutual Funds
0.93% Other Institutional Investors
44.55% Public Companies and
Individual Investors